Camilo Lis, MD, Clin Pharm’s Post

🌟 Exciting News! 🌟   The June Edition of BioProcess International has published a new article featuring Pamela Whalley, Associate Director CMC, on the topic presented at Advanced Therapies in Miami, earlier this year: Partnering for Gene Therapy Manufacturing - What is the Key to Success?   In this insightful piece, Pam explores the crucial factors that gene therapy developers must consider when selecting a CDMO (Contract Development and Manufacturing Organization) and highlights the importance of demanding a pilot study to ensure success.   Read the full article here: https://lnkd.in/gynu-mnA   #GeneTherapy #Biotech #CDMO #Pharmaceuticals #BioProcess #ManufacturingSuccess #HealthcareInnovation #BPI #CMC #complement #conference

Global: Cell & Gene Therapy - the next big opportunity in pharma services. Mansfield Advisors' latest Insight Article written by Victor Chua, Senior Partner, and William Johnson, Senior Associate explores this booming end-user market that shows few signs of slowing down. Outsourced services will be instrumental in supporting this market growth and private equity is increasingly focussed on this end market both via CDMOs and tools and equipment manufacturers: ➡ Lykan Bioscience - Now RoslinCT(GHO Capital Partners LLP) ➡ Catalent Pharma Solutions (Novo Holdings) ➡ CELLforCURE by Seqens (SK Capital Partners and Merieux Equity Partners) ➡ Vibalogics, part of Recipharm (EQT Group and Ardian) ➡ Gamma Biosciences (KKR) ➡ PlasmidFactory GmbH - The Minicircle Company (ARCHIMED) ➡ BioAgilytix Labs (Cinven and Cobepa) ➡ Envirotainer (EQT Group and Mubadala) ➡ CRYOPDP (Hivest Capital Partners) ➡ Germfree (EW Healthcare Partners) #lifesciences #healthcare #privateequity European Healthcare Investor Association (E.H.I.A.) Investors in Healthcare

Cell & Gene Therapy is the next market opportunity for investors as pharma outsourcing drives demand for CDMOs and the manufacturers of tools and equipment to support strong growth in demand. READ Mansfield Advisors' latest insight article in Investors in Healthcare here https://lnkd.in/e-Aff5QG #lifesciences #healthcare Victor Chua William Johnson

Thoughts on this? >> Miltenyi Biotec and Translational Health Science Institute collaborate to strengthen R&D in cell and gene therapy - Express Pharma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #competitivemarketing #pharmaceutical

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

🧬Explore the strategic insights from the BioTech Industry Outlook 2024 and discover how to capitalize on emerging trends in cell therapy, gene therapy, and AI-driven drug discovery. Leverage the future of #biotech with insights from MarketsandMarkets. To explore the top trends reshaping the industry in 2024, click here. https://lnkd.in/dsEhiX4J #healthcare #globaltrends #marketanalysis #medtech #healthcarerevolution #futureofhealthcare #marketsandmarkets

Thoughts on this? >> Miltenyi Biotec and Translational Health Science Institute collaborate to strengthen R&D in cell and gene therapy - Express Pharma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #biotech #pharmaceutical

The cell and gene therapy field is booming, but making these life-changing treatments accessible remains a challenge. How can we overcome cost barriers and manufacturing hurdles? Cell and gene therapy manufacturing relies heavily on pen and paper, hindering data sharing and slowing down processes. This can be life-threatening for patients who need timely treatment. We need to embrace digital solutions, both inside and outside the cleanroom, to improve efficiency and ensure patient safety. 👉 Read Clinical Trials Arena's article for expert insights from Autolomous CEO Alexander Seyf, David Smith - BioCentriq, John W. Hadden II - ViroCell Biologics, and Romain du Hecquet de Rauville - EXO Biologics

Are you striving to refine your AAV gene therapy production processes? Facing challenges with scale-down models, production robustness, or raw material variability? Join us at the Bioprocessing Summit, on August 19-22 at Sheraton Boston, to gain strategic insights from 200+ leading viral vector experts. https://lnkd.in/e84zYGj3 Reasons to Attend: - Understand experimental strategies with Dan Odenwelder, Biogen Explore the impact of adherent to suspension transitions with Shaoying Wang, Passage Bio - Discover novel capsid development approaches to enhance commercial viability with Davide Gianni, Biogen - Learn robust producer cell line development strategies from Amit Mathur, Ph.D., Sanofi - Enhance volumetric titers using high-throughput methods with Julien Robitaille, National Research Council Canada Implement cost-effective strategies for clinical development with Frank Agbogbo, Forge Biologics This session forms part of the '2024 Bioprocessing Summit' and is one of 14 full conference programs at the 2024 #chibioprocessingsummit in Boston on August 19-22. These programs cover a wide range of themes, including AI and Digitalization, Cell Therapy, Upstream and Downstream Processing. Join us at the Bioprocessing Summit for a ground-breaking event featuring 1,500 biomanufacturing experts across: 14 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐓𝐫𝐚𝐜𝐤𝐬 including a new stream on "AI and Digitalization" 300+ 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 across the spectrum of biologics, gene, cell, and mRNA therapies 90 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 showcasing innovative bioprocessing technologies and services 100+ 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐨𝐬𝐭𝐞𝐫𝐬 revealing the latest in biomanufacturing and analytics 𝐓𝐰𝐨 𝐏𝐥𝐞𝐧𝐚𝐫𝐲 𝐒𝐞𝐬𝐬𝐢𝐨𝐧𝐬 tackling the current and future challenges in bioprocessing

Explore the innovative therapies and technologies reshaping the landscape of cell and gene therapy in Germany. In the realm of healthcare innovation, cell, and gene therapy are revolutionizing treatment options and offering new hope to patients. Let's delve into the trends, challenges, and opportunities shaping the future of this transformative sector in Germany. Key insights: The emergence of numerous innovative Advanced Therapy Medicinal Products (ATMPs) in recent years, particularly cell and gene therapies, has transformed the treatment landscape for complex and challenging diseases such as cancer and genetic disorders. Government, industrial, and academic funding, alongside collaboration among both small and large biopharmaceutical companies, present substantial growth opportunities for the market in the upcoming years. Zolgensma stands out as the premier blockbuster drug among all commercial cell and gene therapies. With a revenue of $1.37 billion in 2022, it is poised to potentially reach $5.00 billion by 2026. The market's vast growth potential is evident for both existing and future/emerging players, driven by a substantial target patient population affected by chronic diseases like cancer, genetic and rare disorders, and other complex ailments. Novartis, Gilead Sciences, Spark Therapeutics, Inc., Amgen, Orchard Therapeutics, Bristol Myers Squibb, BioMarin Pharmaceutical Inc., PTC Therapeutics, Inc., and Organogenesis are the leading players in the Germany cell and gene therapy market. Know more https://ow.ly/oo6N50Rvu2e #germanycellandgenetherapymarket #cellandgenetherapymarket #genetherapymarket #ariztonresearchreveals #focusreportsbyarizton #marketresearch #researchreport #marketinsights #markettrends #marketsize #marketshare #marketgrowth #marketforecast #marketexpansion #healthcareandlifesciences #healthcareindustry #healthcare #lifesciences #medical #biotech